Navigation Links
Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial in Lung Cancer Treatment

PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

"Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy," said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. "This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course."

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSK's ASCIs aim to stimulate the patient's own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly puri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
3. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
4. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... Move Policymakers to "Thoughtful Dialogue"WASHINGTON, Feb. 11 ... the merits of the Medicare Durable Medical Equipment, ... home oxygen leaders call on legislators to carefully ... on beneficiary services and much needed service-oriented jobs. ...
... COLUMBIA, S.C., Feb. 11 The Consortium for ... business, academic and economic development organizations intended to ... board and named Lonnie Emard as the interim ... information systems at BlueCross BlueShield of South Carolina, ...
... all-digital cancer hospital enhances commitment to quality care ... Feb. 11 Cancer Treatment Centers of America ... hospital in Goodyear, Ariz. The 213,000-square-foot facility is ... network. CTCA at Western Regional Medical Center ...
... St George,s, University of London measured recent exposure to tobacco ... Regional Heart Study by measuring the levels of cotinine - ... points 20 years apart. A blood cotinine level above 0.7ng/mL ... a heart attack (2), and other studies have suggested that ...
... 2009 "The House of Representatives and the Senate ... payment, on health care reform in the economic stimulus ... American College of Physicians, said today. ... that will provide adequate funding for critical health care ...
... Feb. 11 Z Trim Holdings,(OTC Bulletin Board: ZTHO), ... Valley,s E.D. Smith "Garden Goodness",French Style Dressing is made ... panel. , E.D. Smith, a ... being,the #1 store brand supplier of pourable dressings in ...
Cached Medicine News:Health News:As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 3Health News:Electronic Health Record Advances Patient-Centered Cancer Care 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 3Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 4
... The Vasculight VS system improves the ... (sun-induced freckles), most benign brown pigments, telangiectasias, ... of Intense Pulsed Light (IPLTM) treats pigmentary ... The unique, combined approach of IPL and ...
... The new IPL Quantum DL ... technology with the reliability and simplicity ... Its modular and upgradeable design protects ... the SR mode for IPL skin ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: